Department of Pediatrics, Federal University of Goiás, Goiania, Goiás, Brazil.
Emerg Infect Dis. 2013 Apr;19(4):589-97. doi: 10.3201/eid1904.121198.
Pneumonia is most problematic for children in developing countries. In 2010, Brazil introduced a 10-valent pneumococcal conjugate vaccine (PCV10) to its National Immunization Program. To assess the vaccine's effectiveness for preventing pneumonia, we analyzed rates of hospitalization among children 2-24 months of age who had pneumonia from all causes from January 2005 through August 2011. We used data from the National Hospitalization Information System to conduct an interrupted time-series analysis for 5 cities in Brazil that had good data quality and high PCV10 vaccination coverage. Of the 197,975 hospitalizations analyzed, 30% were for pneumonia. Significant declines in hospitalizations for pneumonia were noted in Belo Horizonte (28.7%), Curitiba (23.3%), and Recife (27.4%) but not in São Paulo and Porto Alegre. However, in the latter 2 cities, vaccination coverage was less than that in the former 3. Overall, 1 year after introduction of PCV10, hospitalizations of children for pneumonia were reduced.
肺炎对发展中国家的儿童最为成问题。2010 年,巴西将 10 价肺炎球菌结合疫苗(PCV10)引入国家免疫计划。为了评估疫苗预防肺炎的效果,我们分析了 2005 年 1 月至 2011 年 8 月期间所有病因导致肺炎的 2-24 月龄儿童的住院率。我们使用国家住院信息系统的数据,对巴西 5 个数据质量好且 PCV10 疫苗接种覆盖率高的城市进行了中断时间序列分析。在分析的 197975 例住院中,30%是肺炎。在贝洛奥里藏特(28.7%)、库里蒂巴(23.3%)和累西腓(27.4%),肺炎住院率显著下降,但在圣保罗和阿雷格里港没有下降。然而,在后两个城市,疫苗接种覆盖率低于前三个城市。总体而言,在引入 PCV10 1 年后,儿童肺炎住院率降低。